Susvimo (ranibizumab port delivery system) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Susvimo (ranibizumab port delivery system) / Roche
READ-4, NCT02511067: Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The Study

Withdrawn
2
0
NA
Tocilizumab, Actemra, Ranibizumab, Lucentis, Susvimo
University of Nebraska, Genentech, Inc.
Diabetic Macular Edema
10/16
10/16
LADDER, NCT02510794: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Checkmark LADDER trial in neovascular AMD
Jul 2018 - Jul 2018: LADDER trial in neovascular AMD
Checkmark From LADDER trial in nAMD at ASRS 2018 [screenshot]
Jul 2018 - Jul 2018: From LADDER trial in nAMD at ASRS 2018 [screenshot]
Completed
2
225
US
Ranibizumab, Lucentis®
Genentech, Inc.
Macular Degeneration
04/18
03/19

Download Options